Matinas BioPharma
MTNB
30 hedge funds and large institutions have $6.6M invested in Matinas BioPharma in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 11 closing their positions.
1.39% less ownership
Funds ownership: 8.97% → 7.58% (-1.4%)
21% less funds holding
Funds holding: 38 → 30 (-8)
67% less capital inflows, than outflows
Capital inflows: $268K | Capital outflows: $812K
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$116K |
| 2 |
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
+$70.3K |
| 3 |
Renaissance Technologies
New York
|
+$44.5K |
| 4 |
Boothbay Fund Management
New York
|
+$18.4K |
| 5 |
Private Advisor Group
Morristown,
New Jersey
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paloma Partners
Greenwich,
Connecticut
|
-$138K |
| 2 |
Morgan Stanley
New York
|
-$137K |
| 3 |
Goldman Sachs
New York
|
-$87K |
| 4 |
LMR Partners
London,
United Kingdom
|
-$86K |
| 5 |
BlueCrest Capital Management
St Helier,
Jersey
|
-$72.8K |
MTNB Hedge Fund Activity: Q3 2018 in Review
30 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2018, worth a combined $6.6M — up 80% from $3.66M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MTNB and 3 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Raymond James Financial Services Advisors, adding an estimated $116K. The largest seller was Paloma Partners, exiting entirely with an estimated $138K sold.
- 30 institutional investors held Matinas BioPharma (MTNB) as of Q3 2018, down from 38 in Q2 2018.
- Funds reported $6.6M of Matinas BioPharma stock for Q3 2018, up 80% quarter-over-quarter.
- 3 funds opened new Matinas BioPharma positions in Q3 2018 and 11 closed out, a net change of -8 holders.
- The largest Matinas BioPharma buyer in Q3 2018 was Raymond James Financial Services Advisors, an estimated $116K added.
- The largest Matinas BioPharma seller in Q3 2018 was Paloma Partners, an estimated $138K sold.
Based on aggregated 13F filings for Q3 2018.